Article info

Download PDFPDF

Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials

Authors

  • Ye-Xuan Cao Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Sha Li Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Hui-Hui Liu Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Jian-Jun Li Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Jian-Jun Li; lijianjun938{at}126.com
View Full Text

Citation

Cao Y, Li S, Liu H, et al
Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials

Publication history

  • Received February 14, 2018
  • Revised August 22, 2018
  • Accepted August 30, 2018
  • First published October 4, 2018.
Online issue publication 
October 04, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.